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appearance of further manifestations in incomplete ASSD. Finally,
we collected 225 patients (58 males and 167 females) with a median
follow-up of 80 months. At the onset, complete ASSD were 44 and
incomplete 181. Patients with incomplete ASSD had frequently only
1 of the classic triad findings (110 cases), in particular, isolated arthritis
in 54 cases, isolated myositis in 28 cases, and isolated ILD in 28 cases.
At the end of follow-up, complete ASSD were 113, incomplete 112.
Only 5 patients had an isolated arthritis, only 5 an isolated myositis,
and 15 an isolated ILD. During the follow-up, 108 patients with
incomplete forms developed further manifestations. Single main feature
onset was the main risk factor for the ex novo appearance of further
manifestation. ILD was the prevalent ex novo manifestation (74 cases).
In conclusion, ASSD is a condition that should be carefully considered
in all patients presenting with arthritis, myositis, and ILD, even
when isolated. The ex novo appearance of further manifestations in
patients with incomplete forms is common, thus indicating the need
for an adequate clinical and instrumental follow-up. Furthermore, the
study clearly suggested that in ASSD multidisciplinary approach invol-
ving Rheumatology, Neurology, Pneumology, and Internal Medicine
specialists is mandatory.
(Medicine 94(32):e1144)
INTRODUCTION
A ntisynthetase syndrome (ASSD) is a connective tissuedisease characterized by the classic triad arthritis, myositis,
and interstitial lung disease (ILD).1–3 Raynaud’s phenomenon,
mechanic’s hands, and fever are other relevant but less
prevalent clinical findings.1,4 The most frequent antisynthetase
antibody is anti Jo-1, directed against the histidyl-tRNA synthe-
tase, whereas other antisynthetase specificities (eg, anti-PL-7,
PL-12, EJ, KS, OJ, YRS, Zo) are less frequently identified.2,5
The literature data have shown that the clinical phenotype of
ASSD is generally associated with the underlying specificity
of antisynthetase antibody5: patients with anti Jo-1 antibodies
had higher frequencies of myositis, polyarthritis, and ILD,
whereas ‘‘isolated ILD’’ is typical of anti-PL7 and anti-PL12
antibodies.
However, the clinical presentation of anti Jo-1 ASSD
varies greatly, with cases presenting without the classic
triad.2,5–10 In these patients, the clinical picture may evolve
during follow-up.6 Furthermore, ASSD is characterized by a
large heterogeneity in the severity of clinical findings,5,11,12 in
particular, for joint involvement, ranging from simple polyar-
thralgias,5 to a symmetrical polyarthritis,6 and that may be also
seropositive,13,14 for both Ig-M rheumatoid factor (RF) and
anti-cyclic citrullinated peptide antibodies (ACPA).
Despite these sparse data, no previous studies have
specifically analyzed the presentation pattern of the disease
and its variations over time, leaving the disease course of ASSD
poorly understood. For this reason, we set up this multicenter
international retrospective study including anti Jo-1 positive
ASSD to assess the disease course and outcomes of these
patients. Our hypothesis is that anti Jo 1 positive patients
frequently presented with an incomplete ASSD and that the
ex novo occurrence of further manifestations in this setting is
really common.
METHODS
Patients
Cavagna et alTwenty-four rheumatology centers from Italy, Spain,
Germany, and the USA were involved in the study. We included
patients with at least 2 anti Jo-1 positive tests, with 1 or more
2 | www.md-journal.comfindings between arthritis, myositis, and ILD, and that signed
the informed consent as approved by the local Institutional
Ethics Board. Type and characteristics of clinical features,
outcomes, laboratory and instrumental investigations, at the
onset and during follow-up, were retrospectively collected.
As previously described,7 ILD was defined instrumentally
by a restrictive pulmonary function test pattern (Forced Vital
Capacity (FVC)  80%, Forced Expiratory Volume in the first
second (FEV1)/FVC 70%, decreased or normal FEV1, and/or
<20% reduction in diffusing capacity of the lung for carbon
monoxide), after excluding other causes different from ILD, and/
or by signs of alveolitis/fibrosis on high-resolution computed
tomography (HRCT).7 ILD presentation was defined as acute/
subacute when dyspnoea began acutely and progressed rapidly
(within 4–6 weeks from symptom onset), chronic when dyspnoea
began insidiously and progressed slowly, and asymptomatic when
lung involvement was only instrumental. Screening for ILD
occurrence was regularly performed during follow-up.
Patients with muscle enzyme elevation (creatinine phos-
phokinase and/or aldolase) and the presence of typical electro-
myography alterations and/or compatible muscle biopsy
findings were considered as having muscle involvement. Myo-
sitis onset was defined as classic (muscle strength deficit) or
hypomyopathic (instrumental/laboratory evidence of muscle
impairment without strength deficit). Muscle enzymes were
regularly assessed during follow-up.
Arthritis occurrence (joints swelling and tenderness
required) and its presentation pattern (eg, symmetrical polyar-
thritis, oligoarticular/asymmetrical arthritis), fever, mechanic’s
hands, and Raynaud’s phenomenon were assessed clinically.
Plain X-rays were performed to identify joint erosions.
The onset of ASSD was considered from the first pulmon-
ary, muscular or joint symptom. Clinical features onset was
considered concurrent in cases of <3 months of delay between
manifestations’ presentation. For practical purposes, patients
with arthritis, ILD, and myositis were defined as having a
complete ASSD, whereas patients lacking at least one of these
features were defined as having an incomplete form.
Autoantibody Profiling
Autoantibodies were considered positive after 2 tests
confirmations and with at least 1 positivity obtained in the
leading reference/tertiary center. In leading centers, anti Jo-1
positivity, other additional anti-extractable nuclear antigen spe-
cificities, IgM-RF and ACPA were tested by well-validated
methods (Appendix 1).
Statistical Analysis
Descriptive data were reported as absolute and relative
frequencies, mean and standard deviation, median, and inter-
quartile range (IQR) based on the type of the variable distri-
bution. Comparison between groups was firstly tested by the
chi-squared test, t test, or Mann–Whitney test. The association
between clinical and laboratory variables with disease pro-
gression were modeled using logistic regression models, both
univariate and multivariate. Given the lack of knowledge on
prespecified confounders, all the candidate variables tested in
the univariate models were retained in the construction of the
full, adjusted model. Standard diagnostic tests and goodness of
fit were systematically assessed. The results are presented as
Medicine  Volume 94, Number 32, August 2015odds ratios (OR) and 95% confidence intervals (95% CIs).
Analyses were performed using STATA software package
(2009, release 11; StataCorp, College Station, TX).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Main Characteristics of Anti Jo-1 Patients at Disease Onset According to Presentation Pattern
Patient Characteristics at the Onset Complete Form Subset Incomplete Form Subset P
Number of patients, % of total 44 (19.5) 181 (80.5) –
Age, yr (median, IQR) 53.5 (46.5–62.0) 53 (42–63) 0.41

Diagnostic delay, mo (median, IQR) 2.5 (2.0–10.5) 10 (2.0–28.5) 0.191

Males/females 10/34 48/133 0.75
Arthritis, n (% of subset) 44 (100) 100 (55) –
RA-like, n (% of arthritis) 32 (72) 65 (65) 0.47
Arthritis IgM-RF positive/patients checked, % 8/42 (19) 36/97 (37) 0.057
Arthritis ACPA positive/patients checked, % 3/36 (8.5) 12/73 (16.5) 0.39
Myositis, n (% of subset) 44 (100) 81 (45) –
Classic onset, n (% of myositis) 32 (73) 61 (75) 0.92
Hypomyopathic onset, n (% myositis) 12 (27) 20 (25)
Interstitial lung disease, n (% of subset) 44 (100) 70 (38.5) –
Acute/subacute onset, n (% of ILD) 17 (38.5) 29 (41.5) 0.90
Chronic onset, n (% of ILD) 16 (36.5) 26 (37)
Asymptomatic onset, n (% of ILD) 11 (25) 15 (21.5)
Anti-Ro positive/patients checked, % 29/41 (71) 89/178 (50) 0.026
Fever/patients checked, % 14/43 (32.5) 43/179 (24) 0.34
Mechanic’s hands/patients checked, % 9/42 (21.5) 33/175 (19) 0.87
Raynaud’s phenomenon/patients checked, % 12/42 (28.5) 40/179 (22.5) 0.51
eum
equ
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We included in the study 225 patients (58 males and 167
ACPA¼ anti-cyclic citrullinate peptide antibodies; IgM-RF¼ IgM rh
RA¼ rheumatoid arthritis.
Independent sample T test (if equal variances) or Welch test (if unfemales). Clinical characteristics, according to clinical pheno-
type presentation, have been summarized in Table 1 (at disease
onset) and Table 2 (at the last follow-up).
TABLE 2. Main Features of Anti Jo-1 Patients at Last Follow-Up A
Patient Characteristics
at Last Follow-Up
Com
Form
Number of patients, % of total 113
Age, yr (median, IQR) 61 (5
Disease follow-up, mo (median, IQR) 87 (50.
Males/females 27
Arthritis, n (% of subset) 113
RA-like, n (% of arthritis) 79
Arthritis IgM-RF positive/patients checked, % 32/10
Arthritis ACPA positive/patients checked, % 11/82
Myositis, n (% of subset) 113
Classic onset, n (% of myositis) 80
Hypomyopathic onset, n (% myositis) 33
Interstitial lung disease, n (% of subset) 113
Acute/subacute onset, n (% of ILD) 37
Chronic onset, n (% of ILD) 45
Asymptomatic onset, n (% of ILD) 31
Anti-Ro positive/patients checked, % 62/10
Fever/patients checked, % 43/11
Mechanic’s hands/patients checked, % 36/11
Raynaud’s phenomenon/patients checked, % 50/11
ACPA¼ anti-cyclic citrullinate peptide antibodies; IgM-RF¼ IgM rheum
RA¼ rheumatoid arthritis.
Independent sample T test (if equal variances) orWelch test (if unequal va
Chi-squared test.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Patients’ Characteristics at Disease Onset
Arthritis was observed in 144 patients (64.5%). It was
atoid factor; ILD ¼ interstitial lung disease; IQR¼ interquartile range;
al variances). Others: Chi-squared test.polyarticular and symmetrical in the majority of cases (97, 67%
of arthritis). The remaining patients (47, 33%) had an oligoar-
ticular/asymmetrical arthritis. RF-IgM was positive in 44/139
vailable According to the Presentation Pattern
plete
Subset
Incomplete
Form Subset P
(50) 112 (50) –
3–72) 61 (50–72) 0.99

3–167.5) 70.5 (36.0–134.5) 0.21

/86 31/81 0.62
(100) 59 (52.5) –
(70) 34 (57.5) 0.149
9 (29) 16/58 (27.5) 0.95
(13.5) 5/45 (11) 0.92
(100) 64 (57) –
(71) 45 (70) 0.92
(29) 19 (30)
(100) 76 (68) –
(33) 28 (37) 0.49
(40) 30 (39.5)
(27) 18 (23.5)
9 (57) 56/110 (51) 0.45
2 (38) 35/110 (32) 0.38
1 (32.5) 31/109 (28.5) 0.62
2 (44.5) 32/110 (29) 0.024
atoid factor; ILD ¼ interstitial lung disease; IQR¼ interquartile range;
riances) orWilcoxon rank-sum test (if not normally distributed). Others:
www.md-journal.com | 3
Themedian disease duration was 82months (IQR 40–147),
which was not statistically different between complete and
incomplete forms (P¼ 0.21). In the 41 patients (18%) lost to
Medicine  Volume 94, Number 32, August 2015arthritis patients (31.5%), while ACPA in 15/109 (13.5%). RF-
Ig M was tested in 74 patients without arthritis (91% of subset)
and was positive in 6 cases (8% of assessed patients), ACPA in
60 patients (74% of subset) and were positive in 1 case (1.5% of
assessed patients).
Myositis was evidenced in 125 (55.5%) cases and its
presentation was mainly classic (93 patients, 74.5% of cases).
One hundred fourteen patients (51%) had ILD. Presentation was
acute/subacute in 46 cases (40% of ILD), chronic in 42 (37% of
ILD), and asymptomatic in 26 (23%). Anti-Ro antibodies were
positive in 118/219 patients (54%). Fever was observed in 57/
222 cases (25.5%), mechanic’s hands in 42/217 (19.5%), and
Raynaud’s phenomenon in 52/221 (23.5%). Raynaud’s
phenomenon preceded other manifestations in 9 cases (17%,
median 13 months, IQR 12–48).
Only 44 patients (19.5%) had a complete ASSD. One
hundred ten patients (49%) had only 1 onset finding: arthritis
in 54 cases (49% of subset), ILD and myositis in 28, respect-
ively, (25.5%). The remaining 71 patients (31.5% of total) with
incomplete forms had: arthritis and myositis (28 cases, 39.5% of
this subset); arthritis and ILD (18, 25%); ILD and myositis (25,
35.5%). The median diagnostic delay of anti Jo-1 positive
ASSD was 6 months (IQR 2–21), without statistically signifi-
cant differences between complete and incomplete forms
(P¼ 0.191). The median age at disease onset was 53 years
(IQR 43–63). We did not observe statistically significant
differences in age at disease onset between complete and
incomplete forms (P¼ 0.41). By comparing remaining charac-
teristics, the only statistically significant difference we
observed was that anti-Ro positivity was more frequent in
complete than in incomplete forms (P¼ 0.026). See text in
Supplementary File for first line treatments.
Patients’ Characteristics at the End of Follow-Up
Arthritis was observed in 172 patients (76.5%). It was
polyarticular and symmetrical in the majority of cases (113,
66% of arthritis). The remaining patients (59, 34% of arthritis)
had an oligoarticular/asymmetrical arthritis. IgM-RF was
positive in 48/167 arthritis patients (29%), while ACPA in
16/127 (12.5%). Four of the 6 no-arthritis patients (67%) Ig-
M RF positive at baseline developed arthritis (1 oligoarticular/
asymmetrical, 3 polyarticular symmetrical). The only nonar-
thritis ACPA positive patient at baseline, developed an oligoar-
ticular/asymmetrical arthritis. We observed radiographic
erosions in 36/167 patients (21.5%) with available plain radio-
graphs; 27 patients (75%) had a symmetrical polyarthritis and 9
(25%) had an oligoarticular/asymmetrical arthritis (P¼ 0.085).
IgM-RF was positive in 19 patients (53%) with erosive disease,
and ACPA in 8/29 patients (27.5%). Both were statistically
significantly associated with the occurrence of erosions
(P< 0.001 and P¼ 0.009, respectively). Myositis was disclosed
in 177 cases (79%). The presentation pattern was mainly classic
(125 patients, 71% of myositis). ILD was observed in 189
patients (84%). The pattern of presentation was acute/subacute
in 65 cases (34% of ILD), chronic in 75 (40%), and asympto-
matic in 49 (26%).
The prevalence of patients presenting with arthritis, myo-
sitis, and ILD according to follow-up duration is shown in
Figure 1. Fever was observed in 78/222 cases (35%),
mechanic’s hands in 67/220 (30%), and Raynaud’s phenom-
enon in 82/222 (37%).
Cavagna et alWith respect to disease onset, 107 of 181 (59%) patients
with incomplete forms developed further manifestations within
a median time of 12 months (IQR 6–40.8). Feature progression
4 | www.md-journal.comwas observed in 85 patients with 1 manifestation onset (77% of
this subset) and in 22 patientswith 2manifestations onset (31%of
this subset). In 19 patients with 1 feature onset, clinical pro-
gression occurred in 2 different stages, the first in median at
12 months after disease onset (IQR 4.5–23.5 months) and the
second at 24months (IQR11.25–67.5) after the first progression.
Complete and incomplete forms were equally distributed (113
and 112 cases, respectively). The subsequent progression from
incomplete to complete form was observed in 69 cases and the
prevalence of complete forms regularly and steadily increased
with the length of follow-up (Figure 2): 47 patients (43%) had 1
manifestation onset and 22 patients (31%) 2manifestations onset
(P¼ 0.150). Patients with persistent incomplete form had only
arthritis (5 cases, 4.5% of subset), only ILD (15, 13%), only
myositis (5, 4.5%), arthritis and myositis (26, 23%), arthritis and
ILD (28, 25%), and ILD andmyositis (33, 30%). An ex novo ILD
was observed in 74 cases, representing 67% of the patients
without ILD at baseline. Forty-three of 54 patients (80% of
subset) with isolated arthritis at the onset developed ILD, thus
representing more than 50% of ex novo ILD.
FIGURE 1. Over time prevalence of patients with arthritis, myo-
sitis, and Interstitial lung disease. Patients on follow-up.FIGURE 2. Over time prevalence of patients with a complete
antisynthetase syndrome (arthritis, myositis, and interstitial lung
disease). Patients on follow-up.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Analysis of Disease Characteristics Associated With Manifestation Progression in Patients With Incomplete ASSD
Incomplete ASSD
Progression
(N¼ 107)
No Progression
(N¼ 74)
Univariate
Analysis, OR
(95% CI)
Multivariate
Analysis, OR
(95% CI)

Age at onset (median in yr; IQR) 53 (42–63) 52.5 (42–64) 0.99 (0.97, 1.01) 1.00 (0.97, 1.03)
Disease duration (median in mo; IQR) 89 (56–167) 65 (30–122) 1.00 (1.00, 1.01) 1.00 (0.99, 1.01)
Male gender, % 26 (54) 22 (45) 0.75 (0.38, 1.47) 1.06 (0.46, 2.40)
Anti-Ro þ/patients checked, % 55/106 (52) 34/72 (47) 1.20 (0.66, 2.19) 1.32 (0.65, 2.71)
Patients with 1 manifestation onset, % 85/107 (79.5) 25/74 (34) 7.57 (3.86, 14.83) 7.81 (3.74, 16.30)
Patients with 2 manifestations onset, % 22/107 (20.5) 49/74 (66) Reference Reference
Patients with fever at onset, % 21/107 (20) 22/72 (30.5) 0.55 (0.27, 1.10) 0.71 (0.30, 1.67)
Patients with Raynaud’s phenomenon at onset, % 24/107 (22.5) 16/72 (22) 1.01 (0.49, 2.07) 1.00 (0.42, 2.36)
Patients with mechanic’s hands at onset, % 22/104 (21) 11/71 (15.5) 1.46 (0.66, 3.24) 1.92 (0.74, 4.95)
nter
Medicine  Volume 94, Number 32, August 2015 Anti Jo-1 Positive Antisynthetase Syndromefollow-up, the median follow-up duration was 51 months (IQR
24–95); 88.5 months (IQR, 43–153) in the 148 patients still on
follow-up; and 96 months (IQR 59–179) in the 36 patients who
had died. None of the patients lost to follow-up had a complete
form at disease onset. Subsequently, 9 of these patients (22%)
developed a complete ASSD and other 6 (15%) progressed but
not to a complete form. In patients lost to follow-up, the length of
follow-up and the rate of ex novomanifestations appearancewere
statistically reduced with respect to other patients (P¼ 0.002 in
both cases).
Death was disease related in 9 cases (25 % of subset), not
disease related in 17 (49%), and not specified in 10 (26%). After
Doppler echocardiography screening, pulmonary hypertension
was diagnosed by Right Heart Catheterization in 20 patients
(9% of total); in 10 with complete and 10 with incomplete form
and it was the cause of death in 4 cases.
At the end of follow-up, Raynaud’s phenomenon was more
commonly observed in incomplete than in complete ASSD
(P¼ 0.024). For overall prescribed treatments and risk of with-
drawal for side effects/progression on therapy see Figure S1.
Factors Associated With Pattern Disease
Progression
The clustering of factors potentially associated with a
pattern progression and the results of univariate and multi-
variate analyses are shown in Table 3. In both cases, the onset as
1 manifestation was the main risk factor for the subsequent
progression of the clinical pattern.
CONCLUSIONS
To the best of our knowledge, here we described the largest
cohort of anti Jo-1 positive ASSD ever collected. This cohort
also has one of the largest follow-ups ever reported. This is the
first study specifically focused on the course of ASSD clinical
pattern. According to our findings, the course of anti Jo-1
positive ASSD is very variable, in most cases presenting as
an incomplete form, and in particular with a single feature
including arthritis, myositis, or ILD. Patients with incomplete
ASSD¼ antisynthetase syndrome; CI ¼ confidence interval; IQR¼ i
174/181 patients with complete data.forms often develop subsequent manifestations, particularly
ILD, all along the follow-up period (Figure 1) and the frequency
of complete forms increases from 19.5% to 50% of cases.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Progression seems particularly relevant in patients presenting
with a single feature and it may occur even in 2 different stages.
The delay between the development of different manifestations
ranges from a few months to a several years. Differential
diagnosis may be challenging,15 in particular in patients with
arthritis, because presentation pattern is often like rheumatoid
arthritis (RA), with the possible positivity of IgM-RF and
ACPA. Furthermore, IgM-RF and ACPA are associated with
the occurrence of joint erosions, as previously described in other
connective tissue diseases.16,17 According to our results, we
think that the anti Jo-1 should be tested not only in patients with
myositis and ILD but also in subjects with peripheral arthritis,
even though a diagnosis of RA is more likely. Furthermore,
periodic screening for the occurrence of further manifestations
and for ILD in particular is mandatory in incomplete forms.
From the first description in 1976,18 the complexity and
extension of the clinical phenotype in anti Jo-1 positive ASSD
has increased gradually.2,5,19–21 Although included in the
family of myositis, the prevalence of ILD and arthritis is not
particularly different from that of myositis, and ILD is the main
prognostic factor in this setting.19,22 On this basis, in keeping
with Chatterjee et al,2 we think that ASSD is a really complex
entity within the context of different rheumatic conditions.
We confirmed19 that anti Jo-1 ASSD is more common in
women, with a female-to-male ratio of 2:3. Unlike Hervier
et al,5 who reported polyarthralgia as the main form of joint
manifestation, in our series, peripheral polyarthritis was the
most common type of joint involvement. Besides having an RA-
like pattern in the majority of cases, IgM-RF and ACPA were
frequently positive. The positivity of IgM-RF and ACPA was
associated with the occurrence of typical RA erosions, con-
firming previous observations from other series of anti Jo-1
ASSD patients13,14,23 and in other connective tissue dis-
eases.16,17 This finding is of great relevance because arthritis
is frequently the only classic triad finding at disease onset,6 and,
because of that, some patients may be misclassified as having
RA. Furthermore, we observed that the rate of clinical picture
progression in patients presenting only with arthritis is as high
as 90% of cases. According to our results, we could speculate
quartile range; OR¼ odds ratio.that some cases of anti-TNF-alpha-induced anti Jo-1 positive
polymyositis reported in the setting of RA, may be more related
to the natural history of the disease rather than to anti-TNF-
www.md-journal.com | 5
alpha agents. This statement is strengthened by the ab initio
presence of anti Jo-1 antibodies in some of these cases.24–26
Muscle involvement was mainly symptomatic, as well as
ILD, but asymptomatic cases are not uncommon. Strengthening
previous suggestions,27 our data indicate that anti Jo-1 antibody
search should not be restricted to patients with myositis but also
performed in cases of isolated ILDor isolated peripheral arthritis,
even though RA is more likely than any other potential entity. In
fact, the identification of anti Jo-1 is relevant because of its
diagnostic and clinical value. This strategy is mandatory because
the risk of clinical picture progression is high in incomplete
forms, in particular in patients presenting with 1 manifestation.
The delay between the appearances of different manifes-
tations is very long, ranging from a few months to a several
years and this is also possible in 2 different stages. ILD was the
most frequent new finding observed, and 68% of incomplete
forms without ILD at baseline developed ILD during follow-up.
Interestingly, 50% of patients who developed ILD during
follow-up had only arthritis at disease onset, thus re-strengthen-
ing the need for an adequate differential diagnosis and sub-
sequent ILD screening in arthritis patients. We confirmed that
anti-Ro positivity is frequent in anti Jo positive patients,28
showing that it was mainly associated with a complete onset.
The overall survival was good, thus indicating a substantial
good prognosis, independently to the occurrence of established
negative risk factors such as ILD.5,29,30 However, the 18% of
patients were lost to follow-up and we cannot be certain of their
final outcome. Pulmonary hypertension prevalence was not
substantially different from that previously reported in another
large series,31 and it was equally observed in both complete and
incomplete forms.
We are aware of the potential limitations of this study. The
main criticism is that we included patients diagnosed in rheu-
matology units, with a subsequent risk of selection bias, as the
high percentage of onset manifestations of this syndrome
suggested. Nevertheless, we also observed a high number of
patients presenting with only ILD or only myositis. These find-
ings seem to refute a potential selection bias. Another potential
limitation is the retrospective nature of our study, thus with an
increased risk of incompleteness.32,33 Furthermore, we cannot
exclude a possible delay in the diagnosis of asymptomatic ILD
and the temporal timing of 3 months to define contemporary the
onset of different manifestations is arbitrary. Finally, although
proposed,30 so far there are no approved classification criteria for
ASSD, although this point should be considered as a commonly
shared selection bias in all studies up to now published.
In order to reduce the risk of false positive tests and the
subsequent selection bias, we required double test positivity not
only for anti Jo-1 but also for Ig-M RF, ACPA, and anti-Ro.
Even though experimental models are available,34,35
incomplete anti Jo-1 positive ASSD are a perfect model for
pathogenic studies in humans, in particular for ILD. In fact, no
other autoimmune diseases have such a high trend toward the
progression of clinical spectrum. However, taking into account
the frequency of this syndrome, the variability of clinical
presentation and timing of evolution, the networking of a large
number of centers and of different specialists such as Rheu-
matology, Pneumology, Neurology, and Internal Medicine
seems to be the only way available to us to fully understand
the mechanisms underlying ASSD.
In conclusion, our study suggests that anti Jo-1 antibodies
Cavagna et alpositivity should be ruled out in all patients presenting with
isolated myositis, ILD, and arthritis, even though other diag-
noses are possible. The clinical implication of anti Jo-1
6 | www.md-journal.compositivity in these patients is relevant because it may be a
predictor of the ex novo occurrence of further manifestations
during follow-up.
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